In a 40-year-old man receiving semaglutide 1 mg weekly for two months who developed a sharply demarcated, enlarging, mildly scaly hyperpigmented patch on the glabellar region over the past week, what is the most likely diagnosis and recommended management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tinea Faciei (Facial Dermatophytosis) is the Most Likely Diagnosis

This presentation is classic for tinea faciei—a dermatophyte infection of the glabellar/facial region that presents as a sharply demarcated, enlarging, scaly hyperpigmented patch. While semaglutide has rare dermatologic adverse effects reported in the literature, the clinical description (sharply demarcated round patch, mild scaling, spreading pattern, glabellar location) is pathognomonic for a fungal infection rather than a drug reaction.

Clinical Reasoning

The key distinguishing features pointing to tinea faciei include:

  • Sharp demarcation with active spreading border - characteristic of dermatophyte infections
  • Mild scaling - fungal infections classically present with scale at the advancing edge
  • Glabellar location spreading laterally - tinea faciei commonly affects the face in this distribution
  • One week onset after 2 months of stable therapy - drug reactions typically occur within days to weeks of initiation or dose escalation, not after prolonged stable dosing
  • No systemic symptoms - semaglutide-associated skin reactions are typically more generalized

Semaglutide Dermatologic Adverse Effects: What We Know

The available evidence on semaglutide cutaneous reactions shows:

Documented semaglutide-associated skin conditions 1, 2, 3:

  • Drug-induced cutaneous lupus erythematosus (discoid lupus pattern with purple-red plaques, but typically with follicular plugging and loss of pilosebaceous units on biopsy)
  • Acute generalized exanthematous pustulosis-like eruptions (pustular, not hyperpigmented)
  • Leukocytoclastic vasculitis (purpuric, not hyperpigmented patches)

None of these match your patient's presentation. The reported dermatologic reactions occur as generalized eruptions or have distinct morphologies (pustular, purpuric, or lupus-like with specific histologic features), not as localized hyperpigmented scaly patches 1, 2, 3.

Recommended Management Algorithm

Immediate Steps:

  1. Obtain KOH preparation and fungal culture from the active scaling border

    • Scrape scale from the advancing edge
    • KOH will show septate hyphae if tinea faciei
    • Culture confirms dermatophyte species
  2. Do NOT discontinue semaglutide until fungal infection is ruled out

    • Premature discontinuation risks losing glycemic control and weight management benefits 4, 5
    • The temporal relationship (stable dose for 2 months, then sudden onset) argues against drug causation

Treatment Protocol:

If KOH/culture confirms dermatophyte infection:

  • Topical antifungal therapy: Ketoconazole 2% cream or ciclopirox 0.77% cream twice daily for 4-6 weeks
  • For extensive involvement: Consider oral terbinafine 250 mg daily for 2-4 weeks or itraconazole 200 mg daily for 2-4 weeks
  • Continue semaglutide - no drug interaction concerns with antifungals

If fungal studies are negative:

  • Consider punch biopsy to evaluate for:
    • Drug-induced lupus (interface dermatitis, follicular plugging) 1
    • Other inflammatory dermatoses
  • If biopsy confirms drug reaction, then consider semaglutide discontinuation with dermatology and endocrinology co-management

Critical Pitfalls to Avoid

Do not assume drug causation based on temporal association alone. The timing (onset after 8 weeks of stable therapy) is atypical for drug reactions, which typically occur:

  • Within days to 4 weeks of drug initiation 2
  • Shortly after dose escalation 4, 5
  • Not after prolonged stable dosing

Do not discontinue semaglutide without confirming the diagnosis. Semaglutide provides significant cardiometabolic benefits including cardiovascular risk reduction, kidney protection, and weight management 5, 6. Unnecessary discontinuation exposes the patient to:

  • Loss of glycemic control
  • Weight regain (typically occurs rapidly after GLP-1RA cessation) 5
  • Loss of cardiovascular and renal protective effects 5, 6

Consider alternative diagnoses systematically:

  • Tinea faciei (most likely given morphology)
  • Seborrheic dermatitis (less sharply demarcated, more diffuse)
  • Contact dermatitis (history of new topical products?)
  • Post-inflammatory hyperpigmentation from another process

Monitoring During Continued Semaglutide Therapy

While investigating the rash, monitor for established semaglutide adverse effects 4, 5, 7:

  • Gastrointestinal symptoms (nausea, vomiting, diarrhea) - most common side effects
  • Renal function - check creatinine if GI symptoms develop (volume depletion risk)
  • Hypoglycemia - if patient is on concurrent insulin or sulfonylureas
  • Gallbladder symptoms - right upper quadrant pain, nausea after fatty meals

The patient should report any systemic symptoms (fever, joint pain, photosensitivity) that might suggest drug-induced lupus, though this remains unlikely given the isolated facial presentation 1.

The evidence strongly supports treating this as tinea faciei first, continuing semaglutide, and only reconsidering drug causation if fungal studies are negative and biopsy suggests drug-induced pathology.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.